Deliver Your News to the World

QIAGEN CEO Thierry Bernard Named Chairman of AdvaMedDx Board of Directors


AdvaMedDx, a division of AdvaMed representing more than 75 manufacturers of innovative in vitro diagnostic (IVD) tests and technologies in the U.S. and abroad, announced today that Thierry Bernard, CEO of QIAGEN, was elected Chair of the AdvaMedDx Board of Directors. He succeeds Norman Schwartz, CEO of Bio-Rad Laboratories.

Bernard joined QIAGEN in 2015 and was named CEO in 2019. Previously, he worked for 15 years at bioMérieux, where he served in many roles, including as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region.

Thierry Bernard said: “Today, AdvaMedDx is well positioned and has the opportunity to ensure that patients and providers have access to reliable, precise diagnostics. I am excited to lead the AdvaMedDx Board of Directors, and I look forward to working with my colleagues to continue to make a meaningful impact on the diagnostics landscape and improve the lives of countless individuals around the world.”

“I am honored to welcome Thierry Bernard as the new chair of the AdvaMedDx Board. With his decades of experience, Thierry brings a clear vision of the work we can accomplish, and I look forward to working with him and the Dx Board to strengthen our health care system, especially as we come out of the pandemic,” said Advamed President and CEO Scott Whitaker. “For last two years, Norman Schwartz deftly led the Dx Board as the industry rose to meet the unprecedented demand for reliable and accurate diagnostic tests during the pandemic. Thanks to his leadership, this will be strong year for the industry and the patients we serve.”

“We are grateful for Norman Schwartz’s leadership and his commitment to AdvaMedDx was instrumental in navigating our industry through the unprecedented challenges of the pandemic.  His contributions have left an indelible mark on the diagnostics industry, and we are proud to continue building upon the strong foundation he has laid,” said Zach Rothstein, Executive Director of AdvaMedDx.  “I am thrilled to welcome Thierry Bernard as our new Board Chair.  Thierry brings a wealth of experience and a shared commitment to advancing the diagnostics industry.  Together, we will continue to drive innovation and growth, ensuring a brighter future for our members and the patients we serve.”

“It has been an honor to serve as Chair of the AdvaMedDx Board of Directors, working alongside my peers to strengthen our industry and provide patients with the best care possible,” said Norman Schwartz, CEO of Bio-Rad Laboratories and outgoing Chair of the AdvaMedDx Board. “I can think of no one more equipped to lead the organization than Thierry Bernard, and I am confident that under his leadership, the diagnostics industry will continue to meet the growing demand for innovative, effective, and accurate diagnostic tests.”

# # #

AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed members range from the largest to the smallest medical technology innovators and companies. For more information, visit

( Press Release Image: )


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.